
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k071675
B. Purpose for Submission:
New Device
C. Measurand:
Alpha-Fetoprotein (AFP), Beta-2-Microglobulin (B2-M), CA 15-3, CA 19-9, CA 27-
29, CA 125, Carcinoembyronic antigen (CEA), Ferritin, hCG/Beta hCG (human
chorionic gonadotropin), Insulin growth factor-1 (IGF-1), Prostate acid phosphatase
(PAP), Prolactin, Prostate specific antigen (PSA), Prostate specific antigen-free (Free
PSA), Thyroglobulin.
D. Type of Test:
Quality Control Material
E. Applicant:
Bio-Rad Laboratories
F. Proprietary and Established Names:
Liquichek Tumor Marker Control Levels 1, 2 and 3
G. Regulatory Information:
Product Code Classification Regulation Section Panel
JJY Class I 21 CFR 862.1660 Chemistry 75
Quality control material (assayed
and unassayed)
H. Intended Use:
1. Intended use(s):
Liquichek Tumor Markers Control is intended for use as an assayed quality
control material to monitor the precision of laboratory testing procedures for the
analytes listed in the package insert.
2. Indication(s) for use:
Same as above
3. Special conditions for use statement(s):
Prescription use
4. Special instrument requirements:
Not applicable
I. Device Description:
Liquichek Tumor Markers Control is prepared from human source material with
added constituents of human and animal origin, chemicals, stabilizers, and
preservatives (cocktail of preservatives in which the concentration of any one
ingredient does not exceed 0.1%). The controls are provided in ready-to-use liquid
form.
J. Substantial Equivalence Information:
Liquichek Tumor Markers Control claims substantial equivalence to the Lyphocheck
Tumor Markers Control (k011579).
1

[Table 1 on page 1]
	Product Code			Classification			Regulation Section			Panel	
JJY			Class I			21 CFR 862.1660
Quality control material (assayed
and unassayed)			Chemistry 75		

--- Page 2 ---
Similarities
Item Device Predicate
Intended Use Liquichek Tumor Lyphochek Tumor
Markers Control is Markers Control is
intended as an assayed intended as an assayed
quality control material to quality control material
monitor the precision of to monitor the precision
laboratory testing of laboratory testing
procedures for the procedures for the
analytes listed in the analytes listed in the
package insert. package insert.
Differences
Item Device Predicate
Analytes Alpha-Fetoprotein (AFP), ACTH, Aldosterone,
Beta-2-Microglobulin Alpha-Fetoprotein
(B2-M), CA 15-3, CA (AFP), Beta-2-
19-9, CA 27-29, CA 125, Microglobulin (B2-M),
Carcinoembyronic CA 15-3, CA 19-9, CA
antigen (CEA), Ferritin, 27-29, CA 50, CA 125,
hCG/Beta hCG (human CASA, Calcitonin,
chorionic gonadotropin), Carcinoembyronic
Insulin growth factor-1 antigen (CEA), Ferritin,
(IGF-1), Prostate acid hCG/Beta hCG (human
phosphatase (PAP), chorionic gonadotropin),
Prolactin, Prostate Neuron specific enolase,
specific antigen (PSA), Prostate acid phosphatase
Prostate specific antigen- (PAP), Prolactin,
free (Free PSA), Prostate specific antigen
Thyroglobulin (PSA), Prostate specific
antigen-free (Free PSA).
Levels Level 1, 2 and 3 Level 1 and 2
Reagent Preparation Liquid Lyophilized
Matrix Human and animal serum Human serum
albumin
Preservatives Contains preservatives Does not contain
preservatives
Storage -20oC to -70oC 2oC to 8oC;
-10oC to -20oC for 30
days after reconstitution
Stability, open IGF-1: 15 days; All other Ferritin and CA 27-29: 6
analytes 30 days at 2oC to days; ACTH, Calcitonin,
8oC. Free PSA, PSA
immediately; all other
analytes 14 days at 2oC
to 8oC
2

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
Intended Use			Liquichek Tumor
Markers Control is
intended as an assayed
quality control material to
monitor the precision of
laboratory testing
procedures for the
analytes listed in the
package insert.			Lyphochek Tumor
Markers Control is
intended as an assayed
quality control material
to monitor the precision
of laboratory testing
procedures for the
analytes listed in the
package insert.		
								
Differences								
	Item			Device			Predicate	
Analytes			Alpha-Fetoprotein (AFP),
Beta-2-Microglobulin
(B2-M), CA 15-3, CA
19-9, CA 27-29, CA 125,
Carcinoembyronic
antigen (CEA), Ferritin,
hCG/Beta hCG (human
chorionic gonadotropin),
Insulin growth factor-1
(IGF-1), Prostate acid
phosphatase (PAP),
Prolactin, Prostate
specific antigen (PSA),
Prostate specific antigen-
free (Free PSA),
Thyroglobulin			ACTH, Aldosterone,
Alpha-Fetoprotein
(AFP), Beta-2-
Microglobulin (B2-M),
CA 15-3, CA 19-9, CA
27-29, CA 50, CA 125,
CASA, Calcitonin,
Carcinoembyronic
antigen (CEA), Ferritin,
hCG/Beta hCG (human
chorionic gonadotropin),
Neuron specific enolase,
Prostate acid phosphatase
(PAP), Prolactin,
Prostate specific antigen
(PSA), Prostate specific
antigen-free (Free PSA).		
Levels			Level 1, 2 and 3			Level 1 and 2		
Reagent Preparation			Liquid			Lyophilized		
Matrix			Human and animal serum
albumin			Human serum		
Preservatives			Contains preservatives			Does not contain
preservatives		
Storage			-20oC to -70oC			2oC to 8oC;
-10oC to -20oC for 30
days after reconstitution		
Stability, open			IGF-1: 15 days; All other
analytes 30 days at 2oC to
8oC.			Ferritin and CA 27-29: 6
days; ACTH, Calcitonin,
Free PSA, PSA
immediately; all other
analytes 14 days at 2oC
to 8oC		

--- Page 3 ---
K. Standard/Guidance Document Referenced (if applicable):
None referenced
L. Test Principle:
Not applicable.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Not applicable.
b. Linearity/assay reportable range:
Not applicable.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability: there are no claims for traceability made.
Stability:
Open vial stability: All analytes are stable for 30 days at 2oC to 8oC with the
following exception: Insulin-like growth factor (IGF-1) is stable for 15 days.
Shelf life: two-years.
Expected values: Value assignments for each lot are performed by
independent manufacturers and laboratories using FDA
exempt/cleared/approved tests. Mean values for the three levels are derived
from replicate analysis. It is recommended that each laboratory establish its
own values and acceptable range. Values and ranges are lot specific.
d. Detection limit:
Not applicable.
e. Analytical specificity:
Not applicable.
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable.
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
3

--- Page 4 ---
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
4